Who can be treated — and what the injection actually does

Shoulder cartilage damage is an explicit indication for ChondroFiller injection — not an off-label application. The treatment is offered alongside the knee, hip, ankle, elbow, and wrist at London Cartilage Clinic on Harley Street, where Professor Paul Lee first introduced the injectable technique to the UK.

The pathway is an outpatient procedure under real-time ultrasound guidance: no general anaesthetic, no surgical incision, and a typical appointment of around 30 to 45 minutes. A collagen gel is delivered directly into the glenohumeral joint space, where it polymerises in situ to form a viscoelastic scaffold over the worn articular surface. That scaffold then recruits the patient's own progenitor cells, which migrate in and begin laying down new cartilage matrix — a process called acellular matrix-induced chondrogenesis.

Unlike surgical ChondroFiller variants, the injectable pathway carries no upper age limit and no defect-size ceiling. Patients with diffuse glenohumeral wear, not only those with well-defined focal lesions, can be considered for treatment.

Clinical evidence specific to the glenohumeral joint is limited: no randomised controlled trial has been conducted in this joint alone. The evidence base draws on published multi-joint cohorts — principally knee and hip — and on institutional clinical experience at London Cartilage Clinic, where shoulder patients have been treated on this pathway.

How the collagen scaffold works once it is in the joint

"Acellular" is the word that surprises most patients: the gel contains no donor stem cells, no blood-derived growth factors, and nothing sourced from another person. ChondroFiller (Meidrix Biomedicals GmbH) is a purified Type I collagen hydrogel, regulated as a CE-marked Class III medical device, and it is entirely the patient's own biology that performs the regenerative work.

The process has two distinct phases. In the first — physical — phase, the injected collagen transitions from liquid to viscoelastic solid within minutes of entering the glenohumeral joint space, conforming to the contours of the damaged articular surface and forming a stable, cushioning matrix layer. This gelation takes place in a fluid synovial environment: there is no requirement to prepare or dry the joint surface beforehand, which is what makes in-clinic injection feasible rather than a theatre-based procedure.

The second phase is biological. Progenitor cells from the surrounding synovium and from the subchondral bone migrate into the scaffold, drawn in by its collagen architecture. In ex vivo osteochondral laboratory modelling, ChondroFiller produced a 2.4-fold increase in DNA content within 14 days, significantly above untreated defect controls. This is laboratory evidence for cell recruitment, not a clinical outcome figure — but it illustrates the underlying design logic: rather than supplying repair cells directly, the scaffold creates conditions that prompt the joint's own biology to respond.

Candidacy — defect types, OA grades, and who may not benefit

The clinical range for ChondroFiller injection in the shoulder is intentionally broad. The injectable pathway carries no upper age limit and no restriction on defect size — distinctions from surgical cartilage repair procedures such as ACI, MACI, or OATS, which require stricter patient selection. Realistic candidates include patients with:

• Post-traumatic focal chondral damage in the glenohumeral joint
• Grade III/IV articular cartilage lesions, whether confined or more diffuse
• Early-to-mid osteoarthritis with partial- or full-thickness chondral loss
• Diffuse glenohumeral surface degeneration, including Kellgren-Lawrence Grade IV

The one meaningful caution in the evidence comes from a hip cohort published in the Journal of Hip Preservation Surgery (2021): patients with Tönnis grade 2–3 pre-existing osteoarthritis had poor outcomes with ChondroFiller, whereas those with less advanced disease fared considerably better. That was a surgical rather than injectable series, and no validated shoulder-specific threshold has been established. As a practical proxy for risk stratification, however, it points to a real boundary: where joint destruction is already extensive, the scaffold has less viable articular tissue to interact with, and outcomes are likely to be more modest.

The broad inclusion criteria do not make imaging review optional — they make it more important. MRI or diagnostic ultrasound is needed to map the defect accurately, grade the surrounding joint, and identify patients who sit at or near that boundary. Symptom history alone cannot reliably answer those questions. London Cartilage Clinic reviews imaging as part of the initial assessment before confirming whether the injection pathway is appropriate.

Ultrasound-guided placement into the glenohumeral joint

The accuracy case for ultrasound guidance is concrete: landmark-guided shoulder injections achieve accurate intra-articular placement in roughly 44–50% of cadaveric attempts, depending on the approach used. For a routine corticosteroid or viscosupplement, missed placement is merely inefficient; for a collagen scaffold designed to coat damaged articular cartilage, it would defeat the procedure entirely.

Real-time ultrasound changes the arithmetic. The clinician can visualise the needle tip entering the glenohumeral joint space, confirm its position relative to the articular surfaces, and observe the collagen gel spreading as it is deposited — providing immediate confirmation that the product has reached its target. This matters for safety as much as accuracy: landmark guidance carries a significantly higher risk of iatrogenic cartilage injury, which is a material concern in a joint whose articular surfaces are already compromised.

Multiple refined access routes — anterior, posterior, and modified-posterior approaches — have been described for ultrasound-guided glenohumeral injection in recent literature, all suited to routine clinical use. The clinician selects the approach based on individual anatomy and the location of the defect being treated.

One technique point worth noting: overfilling a defect produces a different tissue response from a flush application. Studies using ChondroFiller in the wrist have shown fibrous tissue formation only in overfilled sites, while flush applications are free of this complication. Real-time imaging allows the injecting clinician to judge volume and spread as the gel is placed, making overfill a manageable rather than unavoidable risk.

The appointment itself is outpatient, takes approximately 30–45 minutes, and requires no general anaesthetic or theatre booking. At London Cartilage Clinic on Harley Street, the injection is delivered under real-time ultrasound guidance as a standalone clinic visit.

Recovery, outcomes, and the evidence behind them

For the first few weeks after injection, the shoulder benefits from protected rather than full activity. Biomechanical in vitro data explain why: early full joint loading produced cartilage damage scores comparable to an unfilled defect, confirming that the collagen scaffold needs time to set stably before it can absorb load. Avoiding forceful overhead movement and heavy lifting during this window is a mechanical necessity, not an arbitrary restriction.

Once stable, published multi-joint injection series report significant reductions in NRS pain scores, improvement on the DASH (Disability of the Arm, Shoulder, and Hand) questionnaire, and measurable increases in grip and pincer strength. Post-treatment MRI scans in these series have confirmed reduced bone marrow oedema, diminished periarticular effusion, and visible joint-space widening. These MRI findings come from clinical practice reporting rather than a controlled shoulder trial.

The most robust peer-reviewed outcome data are from the knee and hip: published cohort studies show IKDC improvements of approximately 30 points in the knee and mHHS improvements of a similar magnitude in the hip, with MOCART cartilage integrity scores reaching 70–87 at 12 months. For the shoulder, no peer-reviewed randomised trial or large prospective cohort has yet been published; shoulder outcomes at present rest on institutional clinical experience at London Cartilage Clinic and findings extrapolated from multi-joint series.

Where long-term joint preservation is the goal — a trajectory consistent with those durable knee and hip results — a maintenance programme of biennial top-up injections is available for appropriate patients.

Combination approaches and booking an assessment

For patients with advanced or end-stage shoulder osteoarthritis, ChondroFiller injection does not have to work alone. At London Cartilage Clinic, where Professor Paul Lee leads the programme, a same-visit combination is available: ChondroFiller (2.3 mL, targeting the articular cartilage surfaces) paired with Arthrosamid, a polyacrylamide hydrogel that acts on the synovial lining rather than on the bone ends. Because the two products work through entirely different mechanisms — one a regenerative collagen scaffold, the other a non-regenerative hydrogel — they should not be treated as interchangeable or collapsed into a single category. For selected patients, an autologous MSC preparation can be added as a third biologic component, providing cellular support to complement the scaffold.

This kind of combination protocol is not a standard offer for every shoulder patient. Suitability depends on imaging findings, OA grade, and what a full clinical assessment reveals — some patients are well served by ChondroFiller injection alone.

ChondroFiller injection is delivered at London Cartilage Clinic on Harley Street under the Liquid Cartilage™ programme — the clinical brand name under which ChondroFiller is offered in the UK. To find out whether your shoulder is suitable, book an assessment at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Ultrasound-Guided Glenohumeral Joint Injection using a Modified Posterior Approach. (2025). https://doi.org/10.31138/mjr.200424.uig https://doi.org/10.31138/mjr.200424.uig
3. [3] Accuracy and safety of two landmark-guided techniques for arthrocentesis and intra-articular injection of the shoulder in dogs. (2025). https://doi.org/10.1111/vsu.14218 https://doi.org/10.1111/vsu.14218
4. [4] Ultrasound-Guided Glenohumeral Joint (Posterior Approach) Injection Technique. (2025). https://doi.org/10.1097/PHM.0000000000002626 https://doi.org/10.1097/PHM.0000000000002626
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
7. [7] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y